Elucidation and pharmacological targeting of tumour checkpoint dependencies
28 Apr 2016
Elucidation and pharmacological targeting of tumour checkpoint dependencies
Identifying myeloid-driven biologies
Metastasis intiation mediated by thrombospondin 2
New technology can potentially overcome CAR T-cell limitations
AML17 Trial results: maximum dosage of daunorubicin in AML
AML during pregancy
Germ line predisposition to leukaemia
The future of haematopathology
Frontline therapy in young patients with myeloma
Genomics of childhood ALL
Cell of origin role in cancer stem cell and GBM phenotype
New RAF-targeted therapeutic shows early promise against tumours with BRAF and RAS mutations